The Variant Forms of Autoimmune Hepatitis

Annals of Internal Medicine

Volumn 125, Issue 7, 1996, Pages 588-598

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; FEMALE; HEPATITIS; HUMAN; IMMUNOLOGY; MALE; REVIEW; SYNDROME;

AUTOIMMUNE DISEASES; FEMALE; HEPATITIS; HUMANS; MALE; SYNDROME;

EID: 0030268388     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-7-199610010-00009     Document Type: Review

References (85)

1. Waldenstrom J. Leber, Blutproteine und Mahrungseiweiss. Deutsche Zeitschrift fur Verdauungs und Stoffwechselkrankheiten. 1950;15:113-21.
2. Beam AG, Kunkel HG, Slater RJ. The problem of chronic liver disease in young women. Am J Med. 1956;21:3-15.
3. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998-1005.
4. Czaja AJ. Chronic active hepatitis: the challenge for a new nomenclature Ann Intern Med. 1993;119:510-7.
5. Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis. 1984;4:1-12.
6. Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci. 1996;40:435-56.
7. Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, 1994. Am J Gastroenterol. 1994;89(8 Suppl):S177-81.
8. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19:1513-20.
9. Terminology of chronic hepatitis. International Working Party. Am J Gastroenterol. 1995;90:181-9.
10. Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci. 1996;41:305-14.
11. Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci. 1986;31:705-11
12. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology. 1993;105:1522-8.
13. Kloppel G, Seifert G, Lindner H, Dammermann R, Sack HJ, Berg PA. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with milochondrial antibodies of different specificity. Virchows Arch A Pathol Pathol Anat. 1977; 373:143-60.
14. Meek F, Khoury EL, Doniach D, Baum H. Mitochondrial antibodies in chronic liver diseases and connective tissue disorders: further characterization of the autoantigens Clin Exp Immunol. 1980;41:43-54.
15. Berg PA, Wiedmann KH, Sayers T, Kloppel G, Lindner H. Serological classification of chronic cholestatic liver disease by the use of two different types of antimitochondrial antibodies Lancet. 1980;2:1329-32.
16. Fussey SP, Guest JR, James OF, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA. 1988;85:8654-8.
17. Fregeau DR, Davis PA, Danner DJ, Ansari A, Coppel RL, Dickson ER, et al. Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex. J Immunol. 1989;142:3815-20.
18. Mutimer DJ, Fussey SP, Yeaman SJ, Kelly PJ, James OF, Bassendine MF. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology. 1989;10:403-7.
19. Van de Water J, Cooper A, Surh CD, Coppel R, Danner D, Ansari A, et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis N Engl J Med. 1989;320:1377-80.
20. Zurgil N, Konikoff F, Bakimer R, Slor H, Shoenfeld Y. Detection of antimitochondrial antibodies: characterization by enzyme immunoassay and immunoblotting. Autoimmunity. 1989;4:289-97.
21. Heseltine L, Turner IB, Fussey SP, Kelly PJ, James OF, Yeaman SJ, et al. Primary biliary cirrhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology. 1990;99:1786-92.
22. Yoshida T, Bonkovsky H, Ansari A, Danner D. Antibodies against mitochondrial dehydrogenase complexes in primary biliary cirrhosis. Gastroenterology. 1990;99:187-94.
23. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology. 1992;103:1290-5.
24. Davis PA, Leung P, Manns M, Kaplan M, Munoz SJ, Gorin FA, et al. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology. 1992;16: 1128-36
25. Geubel AP, Baggenstoss AH, Summerskill WH. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 1976;71:444-9.
26. Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsupputative eholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver. 1984;105-16.
27. Salaspuro MP, Sipponen P, Ikkala E, Kolho L, Makkonen HM, Miettinen TA, et al. Clinical correlations and significance of orceinpositivity in chronic active hepatitis and primary biliary cirrhosis. Ann Clin Res. 1976;8: 206-15.
28. Ludwig J, McDonald GS, Dickson ER, Elveback LR, McCall JT. Copper stains and the syndrome of primary biliary cirrhosis. Evaluation of staining methods and their usefulness for diagnosis and trials of penicillamine treatment. Arch Pathol Lab Med. 1979;103:467-70.
29. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol. 1992;14:325-31.
30. Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sc. 1992;37:1606-11.
31. Weisner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79:200-6.
32. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1990;13:701-6.
33. Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology. 1994;19:609-15.
34. Czaja AJ, Santrach PJ, Moore SB. HLA-DQ associations in type 1 autoimmune hepatitis. Mayo Clin Proc. 1995;70:1154-60.
35. Zetterquist H, Broome U, Einarsson K, Olerup O. HLA class II genes in primary sderosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut. 1992;33:942-6.
36. Mehal WZ, Lo YM, Wordsworth BP, Neuberger JM, Hubscher SC, Fleming KA, et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 1994;106:160-7.
37. Mieli-Vergani G, Lobo-Yeo A, McFarlane BM, McFarlane IG, Mowat AP, Vergani O. Different immune mechanisms leading to autoimmunity in primary sclerosing cholangitis and autoimmune chronic active hepatitis of childhood. Hepatology. 1989;9:198-203.
38. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med. 1985;102:581-7.
39. Roberts S, Poterucha JJ, Gores GJ, Czaja AJ. Overlap between type 1 autoimmune hepatitis and primary sclerosing cholangitis [Abstract]. Hepatology. 1995;22:A129.
40. Czaja AJ. Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am. 1994;23:547-66.
41. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993;18:342-52.
42. Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci. 1995;40:33-40.
43. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology. 1993; 18:816-22.
44. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology. 1995;108: 157-64.
45. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21:613-9.
46. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid therapy. Hepatology. 1994;19:273-9.
47. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology. 1992; 16:13-8.
48. Vento S, Di Perri G, Garofano T, Cosco L, Concia E, Ferraro T, et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis [Letter]. Lancet. 1989;2:926.
49. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology. 1992;102(4 Pt 1):1406-8.
50. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 1992;116:51-3.
51. Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced chronic active hepatitis? Gastroenterology. 1991;101:840-2.
52. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 1995;108:1770-7.
53. Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab. 1986;63:1086-90.
54. Chung YH, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am J Gastroenterol 1993;88:244-7.
55. Schultz M, Muller R, von zur Muhlen A, Brabant G. Induction of hyperthyroidism by interferon-alpha-2b [Letter]. Lancet. 1989;1:1452.
56. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995;22:364-9.
57. Mitoro A, Yoshikawa M, Yamamoto K, Mimura M, Yoshikawa Y, Shiroi A, et al. Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med. 1993;32:327-31.
58. Mayet WJ, Hess G, Gerken G, Rossol S, Voth R, Manns M, et al. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology. 1989;10:24-8.
59. Fattovich G, Betterle C, Brollo L, Pedini B, Giustina G, Realdi G, et al. Autoantibodies during alpha-interferon therapy for chronic hepatitis B. J Med Virol. 1991;34:132-5.
60. Fattovich G, Betterle C, Brollo L, Giustina G, Pedini B, Alberti A. Induction of autoantibodies during alpha interferon treatment in chronic hepatitis B. Arch Virol. Suppl 1992;4:291-3.
61. Weber P, Wiedmann KH, Klein R, Walter E, Blum HE, Berg PA. Induction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferon. J Hepatol. 1994;20:321-8.
62. Cassani F, Muratori L, Manotti P, Lenzi M, Fusconi M, Ballardini G, et al. Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: a reappraisal at the light of hepatitis C virus infection. Gut. 1992;33: 1260-3.
63. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15:572-7.
64. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology. 1992;15:567-71.
65. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105:1824-32.
66. Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med. 1995;123: 32-4.
67. Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L, et al. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol. 1990;11:339-43.
68. Brunner G, Klinge O. [A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis)]. Dtsch Med Wochenschr. 1987;112:1454-8.
69. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology. 1993;18: 10-5.
70. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol. 1995;90:247-9.
71. Goodman ZD, McNally PR, Davis DR, Ishak KG. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologie correlations in 200 cases. Dig Dis Sci. 1995;40:1232-42.
72. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut. 1994;35:260-5.
73. Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol. 1994;18:91-9.
74. Gordon SC, Quattrociocchi-Longe TM, Khan BA, Kodali VP, Chen J, Silverman AL, et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology. 1995;108:1802-9.
75. Czaja AJ. Auto-immune chronic active hepatitis: a specific entity? The negative argument. J Gastroenterol Hepatol. 1990;5:343-51.
76. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc. 1990;65:23-30.
77. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 1993;104:1755-61.
78. Wachter B, Kyriatsoulis A, Lohse AW, Gerken G, Meyer zum Buschenfelde KH, Manns M. Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies. J Hepatol. 1990;11:232-9.
79. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1: 292-4.
80. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology. 1993;18: 1-9.
81. Czaja AJ. Autoimmune hepatitis: current therapeutic concepts. Clin Immunother. 1994;1:413-29.
82. Czaja AJ. Autoimmune hepatitis. Evolving concepts and treatment strategies. Dig Dis Sci. 1995;40:435-56.
83. Brown J, Dourakis S, Karayiannis P, Goldin R, Chiba J, Ohba H, et al. Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology. 1992;15:175-9.
84. Jeffers LJ, Hasan F, De Medina M, Reddy R, Parker T, Silva M, et al. Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. Hepatology. 1992;15:187-90.
85. Greeve M, Ferrell L, Kim M, Combs C, Roberts J, Ascher N, et al. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology. 1993;17:593-8.